Search PubMed⌕ Search

Biomedical subjects

T Palangie

Publications and source records attributed to T Palangie.

65 records · Page 4Linked to original sources
PubMed1978

[Serum beta2-microglobulin and carcino-embryonic antigen in cancerous patients. A preliminary study of 258 cases (author's transl)].

In this preliminary study dealing with beta2-microglobulin (beta2m) levels in the series of 258 patients, two group are considered:--a group of 208 patients with evolutive tumour;--a group of 50 patients with no evolutive tumour. This study shows a significantly higher incidence of cases with elevated levels of carcinoembryonic antigen (CEA) and/or beta2m in group with evolutive cancer than in group with no evolutive cases. These elevated levels of beta2m are not related to other clinical, topographical, evolutive, immunological parameters. But the increase of serum beta2m levels in patients treated with combination of chemo and immunotherapy, may indicate a possible relationship between beta2m levels and lymphocyte activation.

Beta-Globulins↗
PubMed1977

Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial.

Forty-three patients with inoperable and/or recurring malignant gliomas and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m 2 and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m 2 for 2 days) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m 2 for 2 days). These cycles of treatment were repeated as soon as the hematologic restoration was complete. The treatment was well-tolerated and the clinical condition of 31 out of 43 glioblastoma patients improved during the 2 months after the beginning of the treatment. Six out of eight patients with breast cancer metastases, one out of 13 with bronchial cancer metastases, and three out of nine with other types of cancer metastases also benefitted from the treatment. Examination of the results reveals the following characteristics: 1. A low degree of efficiency of this combination in the treatment of brain metastases, except for breast cancer metastases. 2. Absence of complete correlation between the clinical results observed and the cinegammagraphic developments 3. Similarity of the results independent of the initial localization 4. Establishment of a 6-month median survival period, with ten patients at present in a state of apparently complete remission, 180-506 days after beginning of the treatment.

Adult↗
PubMed1977

[Treatment of inoperable glioblastomas using a combination of adriamycin, VM 26 and CCNU].

46 non resectable malignant gliomas adult patients were treated with a combination protocol of chemotherapy with administration of adriamycin, VM 26 and CCNU. The tolerance to this treatment was good except for the delayed hematological toxicity related to cumulative doses of CCNU, which limited after 5 courses of chemotherapy the possibility of further treatment with the same combination. As far as the neurological responses are concerned, 66 per 100 patients were good responders, but we found a poor relation (50%) between the degree of clinical response and regression of tumour volume in brain scan. The median survival of this group of patients was 9 months and 11 patients/46 are still alive in good state 14 months after they entered into this trial. According to these data we discuss the introduction of chemotherapy at the early stage of the disease.

Adult↗
PubMed1976

[Combination chemotherapy in the treatment of polymetastic breast cancer. Comparison of therapeutic effects of 2 methods of sequential drug administration. Role of adriamycin in these combinations].

One thousand and twenty four patients with disseminated breast cancer were submitted to combination chemotherapy. Fifty one patients (group I) were sequentially given VCR, CPM and 5 FU, and seventy three patients (group II) were given ADM, VCR, CPM and 5 FU. The general and haematological tolerance was good and comparable in the both groups of patients: we observed only two severe infectious complications. Bonemarrow hypoplasia, six myocardial ischemia (two of them were lethal) in each group of patients, without any predominance in the group of patients treated with adriamycin. The percentage of objective regression in both groups was respectively: 72% and 71%. The mean duration of response was eight months. The median survival time was 420 days for patients of group I; for patients of group II the median is not obtained at 480 days. This study confirms that responders to chemotherapy significantly increase the mean duration of survival time. However, in this group of responders the presence of the liver metastases is worse prognosis than all other visceral metastases.

Adenocarcinoma↗
PubMed1975

Letter: Effect of BCG on haemopoietic stem cells.

The i.v. administration of living BCG to (DBA/2 X C57Bl/6) Fl mice pushd quickly the quiescent stem cells of bone marrow into S phase of the cell cycle. This treatment can be used to shorten the intervals of hemopoietic restoration after administration of combination cytotoxic chemotherapy.

Animals↗
PubMedDate not supplied

[Hepatic metastases of breast cancer. Analysis of the parameters which influence the response to chemotherapy].

In a serie of 759 patients treated for metastasized cancer of the breast, presence of an hepatic focus was observed in 29 percent of cases. Isolated hepatic metastases were found in 4 percent of cases while in 25 percent they were associated with other tissues. At the time of initial clinical staging, the difference between the hepatic metastases group and the other group stems from the much greater frequency of severity indices in the former group indicating a general and biological transformation of the metastatic tumor(s). At therapeutic staging, the slight effectiveness of medical therapies can be accounted for by the slight tolerance among patients with a secondary hepatic tumor(s). Lastly, it is interesting to note that progesterone receptor presence does not modify the prognosis in hepatic metastases cases.

Adult↗